A phase 2, multicenter, exploratory study, evaluating the treatment effect of surgery plus Gliadel Wafer [carmustine polifeprosan 20 wafer] in patients with metastatic brain cancer.

Trial Profile

A phase 2, multicenter, exploratory study, evaluating the treatment effect of surgery plus Gliadel Wafer [carmustine polifeprosan 20 wafer] in patients with metastatic brain cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2014

At a glance

  • Drugs Carmustine polifeprosan 20 wafer (Primary)
  • Indications Brain cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Inc; Eisai Medical Research; MGI Pharma
  • Most Recent Events

    • 25 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Planned end date changed from 1 Dec 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top